New research confirms need for lung cancer testing
February 1, 2012 by admin · Leave a Comment
Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.
Milk thistle extract stops lung cancer in mice
November 14, 2011 by admin · Leave a Comment
Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions and so stopped the spread of these lung cancers, according to a recent study published in the journal Molecular Carcinogenesis.
Antifolates show promise against NSCLC subtype
November 12, 2011 by admin · Leave a Comment
SAN FRANCISCO Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.
Inhaler treatment for lung cancer
October 10, 2011 by admin · Leave a Comment
Lung cancer patients could receive safer and more efficient treatment through a system being developed by researchers at the University of Strathclyde in Glasgow.
The scientists have devised a method for giving drugs by inhalation to patients through a nebuliser, rather than the current approach of intravenous delivery.
TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
September 20, 2011 by admin · Leave a Comment
Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.
Celecoxib may prevent lung cancer in former smokers
July 5, 2011 by admin · Leave a Comment
PHILADELPHIA Celecoxib may emerge as a potent chemopreventive agent for lung cancer, according to a recent study in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Stem cells from bone marrow save the day
May 11, 2011 by admin · Leave a Comment
New research, published in BioMed Central’s open access journal Stem Cell Research & Therapy, investigates the therapeutic use of human stem cells from bone marrow against acute lung injury and identifies TNF-α-induced protein 6 as a major molecular component of stem cell action.
Findings could lead to a blood test for lung cancer
May 11, 2011 by admin · Leave a Comment
COLUMBUS, Ohio Researchers have identified characteristic patterns of molecules called microRNA (miRNA) in the blood of people with lung cancer that might reveal both the presence and aggressiveness of the disease, and perhaps who is at risk of developing it. These patterns may be detectable up to two years before the tumor is found by computed tomography (CT) scans.
New therapeutic target for lung cancer
March 30, 2011 by admin · Leave a Comment
A new therapeutic target for lung cancer has been discovered by researchers at Seoul National University. It was found that a variant of the protein AIMP2 is highly expressed in lung cancer cells and also that patients demonstrating high expression of this variant show lower survival. The study is published on March 31 in the open-access journal PLoS Genetics.
Experimental radioprotective drug safe for lung cancer patients, says Pitt study
March 21, 2011 by admin · Leave a Comment
PITTSBURGH, March 22 Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute (UPCI) and published in this month’s issue of Human Gene Therapy.



